knowledge -WSS

knowledge

author：knowledge 2025-09-27 16:49:30 - browse：588

Exact Sciences headquarters. -- biotech coverage from STAT — Exact Sciences' headquarters in Madison, Wis. Wikimedia Commons

Exact Sciences reported first-quarter revenues this week that beat market expectations, and the cancer detection company’s executives still believe they’re on track to meet expected 2024 revenue.

That’s usually good news. Yet Exact shares are down nearly 11% on Thursday, dipping to $53.12 within the first few hours of trading. During after-hours trading on Wednesday, shortly after Exact released its financial updates, shares tumbled as low as $47.24.

The seemingly paradoxical result reflects worries about a potential slowdown in future growth at Exact, a $10 billion biotech best known for Cologuard, a colon cancer screening test that detects blood and DNA from stool samples. The test, which first won regulatory approval in 2014, was designed to boost cancer screening rates by providing a more convenient alternative to colonoscopies.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： Assistant physicians can help address the primary care shortage

entertainment

WSS

A woman pleads guilty to fire that kept a Wyoming abortion clinic from opening for a year

5 dead in mass shooting on Caribbean island of St. Vincent: Police

White House Covid adviser calls on docs to combat misinformation

The stock market has soared this year, but will it last? Experts weigh in

The unintended consequences of overturning Roe v. Wade

The stock market has soared this year, but will it last? Experts weigh in

explore

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Dobbs anniversary: the lost opportunity of abortion as health care

Scientists grapple with ethics of stem cell research

Walensky prepares to leave CDC — and Congress — behind

In rare move, senator releases unverified FBI source report alleging Biden bribe

DIEP, the 'gold standard' of breast reconstruction, is under threat

The unintended consequences of overturning Roe v. Wade

DIEP, the 'gold standard' of breast reconstruction, is under threat

Thousands of UK hospital doctors walk out in the latest pay dispute, crippling health services

The cancer drug shortage isn’t new — and neither are the solutions

Information blocking fines are now fair game in health care

leisure time

5 dead in mass shooting on Caribbean island of St. Vincent: Police

Free Covid tests will again be offered to all U.S. households

Neurocrine congenital adrenal hyperplasia trial succeeds

White House Covid adviser calls on docs to combat misinformation

Information blocking fines are now fair game in health care

Information blocking fines are now fair game in health care

focus

entertainment

focus

knowledge